

# 2018 Current Fiscal Year Report: Center for Substance Abuse Prevention Drug Testing Advisory Board

Report Run Date: 06/05/2019 09:33:44 AM

## 1. Department or Agency

Department of Health and Human Services

## 2. Fiscal Year

2018

## 3. Committee or Subcommittee

Center for Substance Abuse Prevention Drug Testing  
Advisory Board

## 3b. GSA Committee No.

852

## 4. Is this New During Fiscal Year?

No

## 5. Current Charter

06/25/2018

## 6. Expected Renewal Date

06/25/2020

## 7. Expected Term Date

## 8a. Was Terminated During FiscalYear?

No

## 8b. Specific Termination Authority

## 8c. Actual Term Date

## 9. Agency Recommendation for Next FiscalYear

Continue

## 10a. Legislation Req to Terminate?

Not Applicable

## 10b. Legislation Pending?

Not Applicable

## 11. Establishment Authority Authorized by Law

## 12. Specific Establishment Authority

42 U.S.C. § 217a, Section 222 of the Public  
Health Service Act

## 13. Effective Date

10/27/1986

## 14. Committee Type

Continuing

## 14c. Presidential?

No

## 15. Description of Committee Scientific Technical Program Advisory Board

## 16a. Total Number of Reports

No Reports for this  
FiscalYear

## 17a. Open 0 17b. Closed 2 17c. Partially Closed 1 Other Activities 0 17d. Total 3 Meetings and Dates

### Purpose

The board will meet in closed session on December 6, 2017, from 10:00am to 4:00pm EST to discuss proposed revisions of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Oral Fluid), evaluation of hair as an alternate matrix for drug testing matrix, and future board activities. These portions of the meeting are closed to the public as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(4) and (9)(B), and 5 U.S.C. App. 2, Section 10(d).

### Start

### End

12/06/2017 - 12/06/2017

The Board will meet in open session on March 20, 2018, from 10:00am to 1:00pm, to provide updates on the Mandatory Guidelines for Federal Workplace Drug Testing Programs, hear from our federal partners and early observations from the synthetic opioid testing implementation, review research data on a marijuana vaping study, and a brief update on the Medical Review Officer (MRO) Guidance Manual and 2018 MRO Guidance Manual Case Studies. The board will meet in closed session on March 20, 2018, from 2:00pm to 3:00pm EDT and on March 21, 2018, from 10:00am to 2:00pm EDT to discuss the proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs (oral fluid), and the Mandatory Guidelines for Federal Workplace Drug Testing Programs (hair specimen). Therefore, these portions of the meeting are closed to the public as determined by the Assistant Secretary, SAMHSA, in accordance with 5 U.S.C. 552b(c)(4) and (9)(B), and 5 U.S.C. App. 2, Section 10(d). 03/20/2018 - 03/21/2018

The board will meet in closed-session via web conference on August 8, 2018, from 9:00am EDT to 5:00pm EDT to discuss the proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs (hair specimens). Therefore, the meeting is closed to the public as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(4) and (9)(B), and 5 U.S.C. App. 2, Section 10(d). 08/08/2018 - 08/08/2018

### Number of Committee Meetings Listed: 3

	Current FY	Next FY
<b>18a(1). Personnel Pmts to Non-Federal Members</b>	\$12,000.00	\$17,000.00
<b>18a(2). Personnel Pmts to Federal Members</b>	\$40,454.27	\$47,525.45
<b>18a(3). Personnel Pmts to Federal Staff</b>	\$140,859.01	\$142,623.89
<b>18a(4). Personnel Pmts to Non-Member Consultants</b>	\$0.00	\$0.00
<b>18b(1). Travel and Per Diem to Non-Federal Members</b>	\$19,188.00	\$19,404.00
<b>18b(2). Travel and Per Diem to Federal Members</b>	\$0.00	\$0.00
<b>18b(3). Travel and Per Diem to Federal Staff</b>	\$0.00	\$0.00
<b>18b(4). Travel and Per Diem to Non-member Consultants</b>	\$0.00	\$0.00
<b>18c. Other(rents,user charges, graphics, printing, mail, etc.)</b>	\$12,578.00	\$12,706.00
<b>18d. Total</b>	\$225,079.28	\$239,259.34
<b>19. Federal Staff Support Years (FTE)</b>	1.00	1.00

### 20a. How does the Committee accomplish its purpose?

The CSAP Drug Testing Advisory Board's recommendations are an essential prerequisite for implementation of new science into regulation and practice. The CSAP Drug Testing Advisory Board provides advice to the Assistant Secretary for Mental Health and Substance Use, SAMHSA, as the Agency responsible for establishing federal agency workplace drug testing policies in accordance with Executive Order 12564, based on an ongoing review of the direction, scope, balance, and emphasis of the Agency's drug testing activities and the drug testing laboratory certification program. The CSAP Drug Testing Advisory Board reviews SAMHSA's program for national laboratory certification for federal workplace drug testing programs as required by Public Law 100-71 and as described in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. It recommends areas for emphasis or de-emphasis, new or changed directions, and mechanisms or approaches for implementing recommendations. The CSAP Drug Testing Advisory Board also reviews the science associated with alternate specimen matrices and new drugs of abuse and the methods necessary to detect their presence.

**20b. How does the Committee balance its membership?**

The CSAP Drug Testing Advisory Board consists of three nonvoting ex officio members who are officers or employees of the United States Government, as the Assistant Secretary for Mental Health and Substance Use, SAMHSA, determines necessary for the CSAP Drug Testing Advisory Board to effectively carry out its functions. The 10 public members are appointed by the Assistant Secretary, SAMHSA. Of the 10 appointed members, 8 are recognized as experts in either analytical forensic toxicology, in specimen collection procedures for regulated drug testing programs, and interpreting drug testing results. The appointed individuals should represent a variety of disciplines related to forensic drug testing, such as experience in a forensic drug testing laboratory, related academic research, toxicological research, the Medical Review Officer community, or technical expertise from other government agencies involved with drug testing issues, including military drug testing programs. Of the additional two appointed members, one shall represent users of SAMHSA's certified drug testing laboratories and drug-free workplace programs and processes and one shall represent individuals tested in federal or federally-regulated workplace drug testing programs. All Board members who are not officers or employees (full-time or permanent part-time) of the United States Government shall serve as Special Government Employees. Appointments are made by paying close attention to experience and expertise as well as equitable gender representation, race/ethnicity representation, and geographic distribution. Board members advise SAMHSA executive leadership on policy and scientific and technical program development.

**20c. How frequent and relevant are the Committee Meetings?**

CSAP Drug Testing Advisory Board convened three times during FY 2018. Four meetings are tentatively scheduled for fiscal year 2019. The CSAP Drug Testing Advisory Board was charged during this fiscal year with evaluating the scientific supportability of the hair matrix as an alternative specimen for the inclusion in the Federal Workplace Drug Testing Programs. That work has proved challenging and time intensive, with many more aspects to examine before a full recommendation can be made. The CSAP Drug Testing Advisory Board also received federal drug testing updates from the Department of Transportation, the Department of Defense, the Nuclear Regulatory Commission, and the Federal Drug-Free Workplace Programs. In addition, the CSAP Drug Testing Advisory Board will continue to assist the Agency in recommending revisions to the Mandatory Guidelines for testing alternative specimens and additional Schedule II drugs, addressing the impact of new drugs of abuse in the workplace, and assessing the methods that are available to detect their use. The CSAP Drug Testing Advisory Board will review the Agency's National Laboratory Certification Program that was established as required by the

Supplemental Appropriations Act of 1987 (Public Law 100-71) and as described in the Mandatory Guidelines.

**20d. Why can't the advice or information this committee provides be obtained elsewhere?**

The CSAP Drug Testing Advisory Board is composed of both scientific and professional members who provide advice to the Assistant Secretary for Mental Health and Substance Use on improving the quality of services for forensic workplace drug testing, assessing the science and technology used in drug analyses, improving the quality of related laboratory services and systems for drug testing, generating standards for laboratory certification for federal workplace drug testing programs, and guiding national policy in these areas. There is no existing committee or other alternative mechanism that can provide the same expert advice as that provided by the CSAP Drug Testing Advisory Board.

**20e. Why is it necessary to close and/or partially closed committee meetings?**

The closed portions of the Board's meetings involve discussions by the Board of proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs, unpublished and confidential research material, and the review of sensitive National Laboratory Certification Program information. These portions of the meetings are closed to the public as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(9)(B) and 5 U.S.C. App. 2, Section 10(d).

**21. Remarks**

NA

**Designated Federal Officer**

Sean J. Belouin Senior Pharmacology and Regulatory Policy Advisor

Committee Members	Start	End	Occupation	Member Designation
Belouin, Sean	01/19/2018	03/14/2019	Senior Pharmacology and Regulatory Policy Advisor, Division of Workplace Programs, CSAP, SAMHSA	Regular Government Employee (RGE) Member
Caldwell, Dolores	11/01/2016	10/31/2020	Managing Partner, Caldwell Everson PLLC	Special Government Employee (SGE) Member
Clouette, Randal	11/01/2016	10/31/2020	Director of Esoteric Testing, Quest Diagnostics, Employer Solutions	Special Government Employee (SGE) Member

Collins, Jennifer	11/01/2014	04/28/2019	Lab Director IV, MedTox Laboratories, Inc., LabCorp Specialty Testing Group	Special Government Employee (SGE) Member
Ferguson, James	10/31/2014	04/28/2019	Medical Director, Professional Health Monitoring Program, FirstLab, Inc.	Special Government Employee (SGE) Member
Flegel, Ronald	11/01/2014	10/31/2018	Director, Division of Workplace Programs, Center for Substance Abuse Prevention, SAMHSA	Ex Officio Member
Green, David	11/01/2016	10/31/2020	Laboratory Director, Substance Abuse Testing, Alere Toxicology Services, Inc.	Special Government Employee (SGE) Member
Harris, Paul	06/07/2016	05/31/2018	Senior Program Manager, Fitness for Duty Programs, U.S. Nuclear Regulatory Commission	Ex Officio Member
Ioanne, Costantino	11/01/2015	10/31/2019	Administrative Assistant to the General President	Special Government Employee (SGE) Member
Lias, Courtney	07/08/2016	05/31/2018	Director Division of Chemistry and Toxicology Devices, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, Food and Drug Administration	Ex Officio Member
Makela, Brian	06/01/2016	05/31/2018	Chemist, Division of Workplace Programs, CSAP, SAMHSA	Regular Government Employee (RGE) Member
Montgomery, Madeline	11/01/2014	10/31/2018	Supervisory Forensic Chemist Examiner/Forensic Toxicologist, Chemistry Unit, Federal Bureau of Investigation	Regular Government Employee (RGE) Member
Moore, Christine	11/01/2014	04/28/2019	Vice President, Toxicology Research and Development, Immunalysis Corporation	Special Government Employee (SGE) Member
Paul, Buddha	11/01/2014	10/31/2018	Scientist	Special Government Employee (SGE) Member
Schaffer, Michael	11/01/2016	10/31/2020	Vice President of Laboratory Operations, Psychomedics Corporation	Special Government Employee (SGE) Member

**Number of Committee Members Listed: 15**

### **Narrative Description**

The Board provides advisory recommendations regarding improvements in the scientific aspects of forensic workplace drug testing, thereby, impacting on the Agency's efforts to prevent substance abuse among federal employees.

**What are the most significant program outcomes associated with this committee?**

Checked if Applies

Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input checked="" type="checkbox"/>
Major policy changes	<input checked="" type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input type="checkbox"/>
Improved service delivery	<input checked="" type="checkbox"/>
Increased customer satisfaction	<input checked="" type="checkbox"/>
Implementation of laws or regulatory requirements	<input checked="" type="checkbox"/>
Other	<input type="checkbox"/>

### Outcome Comments

NA

### What are the cost savings associated with this committee?

Checked if Applies

None	<input type="checkbox"/>
Unable to Determine	<input checked="" type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

### Cost Savings Comments

It is extremely difficult to determine the cost savings associated with identifying a federal employee as positive for an illicit substance.

### What is the approximate Number of recommendations produced by this committee for the life of the committee?

38

### Number of Recommendations Comments

From FY 1994 to FY 2018, the CSAP DTAB produced 38 recommendations. In FY 2011, the CSAP DTAB submitted two recommendations to the SAMHSA Administrator, which were approved by her in January 2012. Recommendation #1: Based on review of the science, DTAB recommends that SAMHSA include oral fluid as an alternative specimen in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. This is still in

progress and has not been cleared by OMB. Recommendation #2: DTAB recommends the inclusion of additional Schedule II prescription medications (e.g., oxycodone, oxymorphone, hydrocodone and hydromorphone) in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. This recommendation was implemented on October 1, 2017. In FY 2015, the CSAP DTAB submitted one recommendation to the SAMHSA Administrator. Recommendation #3: Based on the review of the science, DTAB recommends that SAMHSA pursue hair as an alternative specimen in the Mandatory Guidelines for Federal Workplace Drug Testing Programs, including performance standards that sufficiently address external contamination and hair color impact. This is in progress and SAMHSA is addressing the scientific issues that require additional research before this can be a viable regulated drug testing matrix.

**What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?**

95%

**% of Recommendations Fully Implemented Comments**

Since the beginning of the Board, approximately 95% of the Board's recommendations have been fully implemented without any changes. These recommendations concerned revisions to the Mandatory Guidelines, urine collection handbook, medical review officer manual, and other National Laboratory Certification Program documents and policies.

**What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?**

3%

**% of Recommendations Partially Implemented Comments**

The Board's recommendations regarding changes in the scientific and administrative aspects of the Federal Workplace Drug Testing Programs are occasionally modified by the Department based on comments received from other Health and Human Services agencies; other federal departments, including the Department of Transportation, the Department of Defense, and the Nuclear Regulatory Commission; and the Office of Management and Budget. The oral fluid recommendation is in final stages of approval, and the hair recommendation is still in the evaluation process.

**Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?**

Yes ☒ No ☐ Not Applicable ☐

### Agency Feedback Comments

Feedback is provided to the Board members on the actions taken by the Agency on the Board's recommendations at each Board meeting, by e-mail, or by faxing or mailing documents to the Board members. Additionally, when policies are implemented, Board members are provided copies.

### What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input checked="" type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

### Action Comments

NA

### Is the Committee engaged in the review of applications for grants?

No

### Grant Review Comments

NA

### How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input checked="" type="checkbox"/>
Other	<input type="checkbox"/>

### Access Comments

N/A